company coverage
Novartis AG research (NYSE:NVS)
Coverage of Novartis AG collects dated research on business quality, return drivers, balance-sheet resilience, valuation scenarios, and what would change the thesis for NYSE:NVS.
1 edition linked in this hub.
Coverage
- 9 Sept 2026Novartis paid $12 billion for Avidity. Its lead drug just failed Phase IIINovartis AG (NYSE:NVS) lost 13.9% after three clinical setbacks; the $42.5 billion reaction reaches far beyond one failed drug.